Lycia Therapeutics prices IPO at $18 per share, raises $317.5 million
The clinical-stage degrader company will list on Nasdaq as "LYCA" with shares expected to deliver October 26, 2026.
SEC filing
Latest
2 stories
Friday, October 23
Monday, October 5
Lycia Therapeutics files for IPO, discloses Phase 1 IgE degrader data
The clinical-stage biotech, which applied to list on Nasdaq under "LYCA," reported preliminary results for LCA-0061 and detailed its LYTAC pipeline in an October 5, 2026 S-1 filing.
SEC filing